Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Alnylam Pharmaceuticals Inc patents


Recent patent applications related to Alnylam Pharmaceuticals Inc. Alnylam Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Alnylam Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Alnylam Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Alnylam Pharmaceuticals Inc-related inventors


Dual targeting sirna agents

The invention relates to dual targeting sirna agents targeting a pcsk9 gene and a second gene, and methods of using dual targeting sirna agents to inhibit expression of pcsk9 and to treat pcsk9 related disorders, e.g., hyperlipidemia.. . ... Alnylam Pharmaceuticals Inc

Compositions and methods for inhibiting expression of the lect2 gene

The invention relates to antisense polynucleotide agents targeting the lect2 gene, and methods of using such antisense polynucleotide agents to inhibit expression of lect2 and to treat subjects having a lect2-associated disease, e.g., amyloidosis.. . ... Alnylam Pharmaceuticals Inc

Compositions and methods for inhibiting expression of factor v

The invention relates to a double-stranded ribonucleic acid (dsrna) for inhibiting the expression of factor v, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of factor v. The invention also relates to a pharmaceutical composition comprising the dsrna together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of factor v using the pharmaceutical composition; and methods for inhibiting the expression of factor v in a cell.. ... Alnylam Pharmaceuticals Inc

Serpina1 sirnas: compositions of matter and methods of treatment

The technology described herein relates to double-stranded ribonucleic acid (dsrna) compositions targeting the serpina1 gene, and methods of using such dsrna compositions to inhibit expression of serpina1.. . ... Alnylam Pharmaceuticals Inc

Factor xii (hageman factor) (f12), kallikrein b, plasma (fletcher factor) 1 (klkb1), and kininogen 1 (kng1) irna compositions and methods of use thereof

The present invention relates to rnai agents, e.g., double stranded rnai agents, targeting the kallikrein b, plasma (fletcher factor) 1 (klkb1) gene, the factor xii (hageman factor (f12) gene, or the kininogen 1 (kng1) gene, and methods of using such rnai agents to inhibit expression of a klkb1 gene, an f12 gene, and/or a kng1 gene, and methods of treating subjects having an hereditary angioedema (hae) and/or a contact activation pathway-associated disorder.. . ... Alnylam Pharmaceuticals Inc

Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof

The invention relates to polynucleotide agents targeting an hydroxyacid oxidase (hao1) gene, and methods of using such polynucleotide agents to inhibit expression of hao1 and to treat subjects having an hao1-associated disease, e.g., hyperoxaluria.. . ... Alnylam Pharmaceuticals Inc

Tmprss6 irna compositions and methods of use thereof

The invention relates to rnai agents, e.g., double-stranded rnai agents, targeting the tmprss6 gene, and methods of using such rnai agents to inhibit expression of tmprss6 and methods of treating subjects having a tmprss6 associated disorder, e.g., an iron overload associated disorder, such as β-thalassemia or hemochromatosis.. . ... Alnylam Pharmaceuticals Inc

Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof

The invention relates to double-stranded ribonucleic acid (dsrna) compositions targeting the angptl3 gene, as well as methods of inhibiting expression of angptl3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsrna compositions.. . ... Alnylam Pharmaceuticals Inc

Compositions and methods for inhibition of expression of protein c (proc) genes

The invention relates to double-stranded ribonucleic acid (dsrna) targeting a proc gene, and methods of using the dsrna to inhibit expression of proc.. . ... Alnylam Pharmaceuticals Inc

Biodegradable lipids for the delivery of active agents

The present invention relates to a cationic lipid having one or more biodegradable groups located in the mid- or distal section of a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. ... Alnylam Pharmaceuticals Inc

Modified rnai agents

One aspect of the present invention relates to double-stranded rnai (dsrna) duplex agent capable of inhibiting the expression of a target gene. The dsrna duplex comprises one or more motifs of three identical modifications on three consecutive nucleotides in one or both strand, particularly at or near the cleavage site of the strand. ... Alnylam Pharmaceuticals Inc

Reversir tm compounds

The present invention relates, in general to agents that modulate the pharmacological activity of conjugated sirnas.. . ... Alnylam Pharmaceuticals Inc

Tmprss6 irna compositions and methods of use thereof

The invention relates to rnai agents, e.g., double-stranded rnai agents, targeting the tmprss6 gene, and methods of using such rnai agents to inhibit expression of tmprss6 and methods of treating subjects having a tmprss6 associated disorder, e.g., an iron overload associated disorder, such as β-thalassemia or hemochromatosis.. . ... Alnylam Pharmaceuticals Inc

Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof

The invention relates to double-stranded ribonucleic acid (dsrna) compositions targeting the angptl3 gene, as well as methods of inhibiting expression of angptl3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsrna compositions.. . ... Alnylam Pharmaceuticals Inc

12/07/17 / #20170349901

Hepatitis d virus (hdv) irna compositions and methods of use thereof

The present invention relates to rnai agents, e.g., double-stranded rnai agents, targeting the hepatitis d virus (hdv) genome, and methods of using such rnai agents to inhibit expression of one or more hbv genes and methods of treating subjects having an hdv infection and/or hdv-associated disorder.. . ... Alnylam Pharmaceuticals Inc

12/07/17 / #20170349900

Hepatitis b virus (hbv) irna compositions and methods of use thereof

The present invention relates to rnai agents, e.g., double-stranded rnai agents, targeting the hepatitis b virus (hbv) genome, and methods of using such rnai agents to inhibit expression of one or more hbv genes and methods of treating subjects having an hbv infection and/or hbv-associated disorder, e.g., chronic hepatitis b infection.. . ... Alnylam Pharmaceuticals Inc

11/30/17 / #20170340661

Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof

The present invention relates to rnai agents, e.g., double stranded rnai agents, targeting the patatin-like phospholipase domain containing 3 (pnpla3) gene, and methods of using such rnai agents to inhibit expression of a pnpla3 gene and methods of treating subjects having nonalcoholic fatty liver disease (nafld) and/or a pnpla3-associated disorder.. . ... Alnylam Pharmaceuticals Inc

11/09/17 / #20170321213

Compositions and methods for inhibiting expression of transthyretin

The invention relates to a double-stranded ribonucleic acid (dsrna) targeting a transthyretin (ttr) gene, and methods of using the dsrna to inhibit expression of ttr.. . ... Alnylam Pharmaceuticals Inc

10/26/17 / #20170307608

Methods of treating transthyretin (ttr) mediated amyloidosis

Disclosed herein are methods for reducing or arresting an increase in a neuropathy impairment score (nis) or a modified nis (mnis+7) in a human subject by administering an effective amount of a transthyretin (ttr)-inhibiting composition.. . ... Alnylam Pharmaceuticals Inc

10/26/17 / #20170304459

Methods and compositions for inhalation delivery of conjugated oligonucleotide

The present invention provides an inhalable formulation comprising a ligand conjugated oligonucleotide and particles of a physiologically acceptable pharmacologically-inert carrier.. . ... Alnylam Pharmaceuticals Inc

10/26/17 / #20170304446

Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression

The invention relates to rnai agents, e.g. Double-stranded rnai agents, targeting the hao1 gene, and method of using such rnai agents to inhibit expression of hao1 and methods of treating subjects having, e.g., ph1. ... Alnylam Pharmaceuticals Inc

10/05/17 / #20170283801

Therapeutic compositions

This application relates to therapeutic sirna agents and methods of making and using the agents.. . ... Alnylam Pharmaceuticals Inc

09/28/17 / #20170275626

Modified double-stranded rna agents

One aspect of the present invention relates to double-stranded rna (dsrna) agent capable of inhibiting the expression of a target gene. The sense strand of the dsrna agent comprises at least one thermally destabilizing nucleotide, and at least one said thermally destabilizing nucleotide occurring at a site opposite to the seed region (positions 2-8) of the antisense strand; and the antisense strand of the dsrna agent comprises at least two modified nucleotides that provide the nucleotide a steric bulk that is less than or equal to the steric bulk of a 2′-ome modification, wherein said modified nucleotides are separated by 11 nucleotides in length. ... Alnylam Pharmaceuticals Inc

09/21/17 / #20170268005

Complement component c5 irna compositions and methods of use thereof

The invention relates to irna, e.g., double-stranded ribonucleic acid (dsrna), compositions targeting the complement component c5 gene, and methods of using such irna, e.g., dsrna, compositions to inhibit expression of c5 and to treat subjects having a complement component c5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.. . ... Alnylam Pharmaceuticals Inc

09/14/17 / #20170260527

Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof

The present invention relates to rnai agents, e.g., double-stranded rnai agents, targeting the apolipoprotein c3 (apoc3) gene, and methods of using such rnai agents to inhibit expression of apoc3 and methods of treating subjects having an apoc3 associated disorder, e.g., hypertriglyceridemia.. . ... Alnylam Pharmaceuticals Inc

09/07/17 / #20170253874

Complement component c5 irna compositions and methods of use thereof

The invention relates to irna, e.g., double-stranded ribonucleic acid (dsrna), compositions targeting the complement component c5 gene, and methods of using such irna, e.g., dsrna, compositions to inhibit expression of c5 and to treat subjects having a complement component c5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.. . ... Alnylam Pharmaceuticals Inc

08/24/17 / #20170240892

Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof

The invention relates to polynucleotide agents targeting the serpinc1 (at3) gene, and methods of using such polynucleotide agents to inhibit expression of serpinc1 and to treat subjects having a bleeding disorder, e.g., a hemophilia.. . ... Alnylam Pharmaceuticals Inc

08/24/17 / #20170240890

Gnaq targeted dsrna compositions and methods for inhibiting expression

The invention relates to a double-stranded ribonucleic acid (dsrna) targeting a g-alpha q subunit (gnaq) of a heterotrimeric g gene, and methods of using the dsrna to inhibit expression of gnaq.. . ... Alnylam Pharmaceuticals Inc

08/17/17 / #20170233734

Nucleic acid lipid particle formulations

The present invention relates to lipid nanoparticles containing a biodegradable cationic lipid which provide improved delivery of active pharmaceutical ingredients, such as sirna.. . ... Alnylam Pharmaceuticals Inc

07/20/17 / #20170204418

Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof

The invention relates to polynucleotide agents, e.g., antisense polunucleotide agents, targeting the alas1 gene, and methods of using such agents to alter (e.g., inhibit) expression of alas1 and to treat alas1 associated diseases, e.g., porphyria.. . ... Alnylam Pharmaceuticals Inc

07/20/17 / #20170204411

Methods and compositions for treating insects

Provided herein are methods and compositions for modulating gene expression in insects by administering a composition comprising an rna effector molecule and a delivery agent. Methods are provided for controlling pest populations by inhibiting insect growth, development, survival, reproduction and/or viability. ... Alnylam Pharmaceuticals Inc

07/06/17 / #20170189541

Angiotensinogen (agt) irna compositions and methods of use thereof

The present invention relates to rnai agents, e.g., double-stranded rnai agents, targeting the angiotensinogen (agt) gene, and methods of using such rnai agents to inhibit expression of agt and methods of treating subjects having an agt-associated disorder, e.g., hypertension.. . ... Alnylam Pharmaceuticals Inc

06/29/17 / #20170183659

Polynucleotide agents targeting complement component c5 and methods of use thereof

The invention relates to polynucleotide agents targeting the complement component c5 gene, and methods of using such polynucleotide agents to inhibit expression of c5 and to treat subjects having a complement component c5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.. . ... Alnylam Pharmaceuticals Inc

06/08/17 / #20170159053

Methods and compositions for treating a serpinc1-associated disorder

The invention relates to irna, e.g., double stranded ribonucleic acid (dsrna), compositions targeting the serpinc1 gene, and methods of using such irna, e.g., dsrna, compositions to inhibit expression of serpinc1 and to treat subjects having a serpinc1-associated disease, e.g., a bleeding disorder, such as a hemophilia.. . ... Alnylam Pharmaceuticals Inc

05/04/17 / #20170121709

Compositions and methods for inhibiting expression of factor v

The invention relates to a double-stranded ribonucleic acid (dsrna) for inhibiting the expression of factor v, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of factor v. The invention also relates to a pharmaceutical composition comprising the dsrna together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of factor v using the pharmaceutical composition; and methods for inhibiting the expression of factor v in a cell.. ... Alnylam Pharmaceuticals Inc

04/27/17 / #20170114342

Serpina1 irna compositions and methods of use thereof

The invention relates to rnai agents, e.g., double-stranded rnai agents, targeting the serpina1 gene, and methods of using such rnai agents to inhibit expression of serpina1 and methods of treating subjects having a serpina1 associated disease, such as a liver disorder.. . ... Alnylam Pharmaceuticals Inc

04/20/17 / #the invention features compounds of formula v or xii:

Alnylam Pharmaceuticals, Inc.

. . ... Alnylam Pharmaceuticals Inc

04/20/17 / #20170107511

Oligonucleotide end caps

Modified nucleic acids are described herein, including pharmaceutical compositions comprising the modified nucleic acids, and methods of using the modified nucleic acids.. . ... Alnylam Pharmaceuticals Inc

03/09/17 / #20170067060

Compositions and methods for inhibiting expression of cd274/pd-l1 gene

The invention relates to double-stranded ribonucleic acid (dsrna) compositions targeting the cd274/pd-l1 gene, and methods of using such dsrna compositions to inhibit expression of cd274/pd-l1.. . ... Alnylam Pharmaceuticals Inc

02/16/17 / #20170045536

Quantification of transthyretin and its isoforms

The present invention relates to assays and methods for the detection of transthyretin and its isoforms. Specifically, the assays and methods of the present invention embrace liquid chromatography and mass spectrometry. ... Alnylam Pharmaceuticals Inc

02/16/17 / #20170044591

Methods and compositions for detecting anti-drug antibodies

Assays, methods, reagents and kits for evaluating the level of an antibody against a nucleic acid molecule, e.g., a double-stranded oligonucleotide or rna molecule (e.g., dsrna), are disclosed herein.. . ... Alnylam Pharmaceuticals Inc

02/02/17 / #20170029817

Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated diseases

The present invention provides irna agents, e.g., double stranded irna agents, that target the transthyretin (ttr) gene and methods of using such irna agents for treating or preventing ttr-associated diseases.. . ... Alnylam Pharmaceuticals Inc

02/02/17 / #20170029815

Rnai agents modified at the 4'-c position

One aspect of the present invention relates to double-stranded rnai (dsrna) duplex agent capable of inhibiting the expression of a target gene in vivo. The dsrna duplex comprises one or more 4′-modifications in one or both strand. ... Alnylam Pharmaceuticals Inc

01/05/17 / #20170000815

Lipid formulated dsrna targeting the pcsk9 gene

This invention relates to composition and methods using lipid formulated sirna targeted to a pcsk9 gene.. . ... Alnylam Pharmaceuticals Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Alnylam Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Alnylam Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###